Adding everolimus to fulvestrant improved outcomes for postmenopausal patients with HR-positive breast cancer
Progression-free survival was more than doubled for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy by adding everolimus (Afinitor) to treatment ...
Dec 8, 2016
0
1